On Friday, Lexeo Therapeutics Inc (NASDAQ: LXEO) was 11.30% up from the session before settling in for the closing price of $9.47. A 52-week range for LXEO has been $1.45 – $10.99.
Healthcare Sector giant saw their annual sales slid by -99.98% over the last five years. When this article was written, the company’s average yearly earnings per share was at 37.04%. With a float of $60.28 million, this company’s outstanding shares have now reached $72.99 million.
Lexeo Therapeutics Inc (LXEO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexeo Therapeutics Inc stocks. The insider ownership of Lexeo Therapeutics Inc is 17.40%, while institutional ownership is 77.35%. The most recent insider transaction that took place on Nov 18 ’25, was worth 10,447. In this transaction Chief Executive Officer of this company sold 1,127 shares at a rate of $9.27, taking the stock ownership to the 240,991 shares. Before that another transaction happened on Nov 18 ’25, when Company’s Chief Medical Officer sold 615 for $9.27, making the entire transaction worth $5,701. This insider now owns 72,646 shares in total.
Lexeo Therapeutics Inc (LXEO) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.78 earnings per share (EPS) during the time that was better than consensus figure (set at -0.78) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.95% during the next five years compared to -99.98% drop over the previous five years of trading.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
You can see what Lexeo Therapeutics Inc (LXEO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.52 in one year’s time.
